Trevi Therapeutics, Inc. $TRVI Shares Sold by Cantor Fitzgerald L. P.

Cantor Fitzgerald L. P. cut its stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 49.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 50,861 shares of the company’s stock after selling 49,140 shares during the period. Cantor Fitzgerald L. P.’s holdings in Trevi Therapeutics were worth $465,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its position in shares of Trevi Therapeutics by 4.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company’s stock valued at $195,000 after purchasing an additional 911 shares during the period. Ameritas Investment Partners Inc. raised its position in shares of Trevi Therapeutics by 20.5% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company’s stock worth $70,000 after purchasing an additional 1,300 shares during the last quarter. BIT Capital GmbH raised its position in shares of Trevi Therapeutics by 32.0% during the 3rd quarter. BIT Capital GmbH now owns 6,739 shares of the company’s stock worth $62,000 after purchasing an additional 1,633 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its stake in Trevi Therapeutics by 20.0% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 12,000 shares of the company’s stock valued at $66,000 after buying an additional 2,000 shares in the last quarter. Finally, Profund Advisors LLC lifted its stake in Trevi Therapeutics by 11.3% in the 3rd quarter. Profund Advisors LLC now owns 20,103 shares of the company’s stock valued at $184,000 after buying an additional 2,044 shares in the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Trading Down 4.5%

TRVI stock opened at $10.69 on Thursday. The firm has a 50-day moving average of $11.15 and a two-hundred day moving average of $10.93. Trevi Therapeutics, Inc. has a 12 month low of $4.85 and a 12 month high of $14.39. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -33.41 and a beta of 0.94.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Tuesday, March 17th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.04. As a group, equities analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

More Trevi Therapeutics News

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Needham raised its price target from $22 to $24 and maintained a “buy” — a bullish signal implying substantial upside to current levels. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating with a $19 target, supporting demand from the buy-side. Read More.
• Positive Sentiment: Trevi achieved FDA alignment and plans two pivotal Phase III trials for IPF‑related chronic cough — a major pipeline and de‑risking milestone that materially increases the program’s commercial potential. Read More.
• Positive Sentiment: Q4 results showed EPS of ($0.06), beating consensus (−$0.10), and management provided business updates tied to the Phase 3 plan — supportive near-term fundamentals. Read More.
• Neutral Sentiment: Analyst/market write-ups are re‑examining TRVI valuation after the FDA alignment; these pieces can help inform longer‑term upside but don’t change near‑term cash/clinical timelines. Read More.
• Negative Sentiment: Morgan Stanley trimmed its price target from $19 to $18 while keeping an “overweight” rating — a modest downgrade to upside expectations that may have tempered buying enthusiasm. Read More.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Stifel Nicolaus boosted their price objective on Trevi Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Monday, March 9th. Oppenheimer reiterated an “outperform” rating on shares of Trevi Therapeutics in a research report on Monday, March 9th. Morgan Stanley reduced their price objective on Trevi Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, Leerink Partners raised their price objective on Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Trevi Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $21.33.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.